73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Thermo Fisher Scientific Inc
Suletud
SektorTervishoid
583.24 0.48
Ülevaade
Aktsiahinna muutus
24h
Min
579.29
Max
585.21
Sissetulek | 6M 1.6B |
|---|---|
Müük | 267M 11B |
P/E Sektori keskmine | 33.22 78.892 |
Aktsiakasum | 5.79 |
Dividenditootlus | 0.3 |
Kasumimarginaal | 14.575 |
Töötajad | 125,000 |
EBITDA | 40M 2.8B |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +10.26% upside |
Dividenditootlus Sektori keskmine | 0.30% 2.38% |
|---|---|
Järgmine tulemuste avaldamine | 29. jaan 2026 |
Järgmine dividendimakse kuupäev | 15. jaan 2026 |
Turukapital | 11B 216B |
|---|---|
Eelmine avamishind | 582.76 |
Eelmine sulgemishind | 583.24 |
Uudiste sentiment
By Acuity
29%
71%
68 / 374 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Thermo Fisher Scientific Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Thermo Fisher Scientific Inc Prognoos
Hinnasiht
By TipRanks
10.26% tõus
12 kuu keskmine prognoos
Keskmine 640.3 USD 10.26%
Kõrge 750 USD
Madal 570 USD
Põhineb 21 Wall Streeti analüütiku instrumendi Thermo Fisher Scientific Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
68 / 374 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
Live chat